Compare Incyte Corporation (INCY) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs ProShares UltraPro Short QQQ ETF — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while ProShares UltraPro Short QQQ ETF trades at $41.04. The key difference: Incyte Corporation is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals.
| INCY | SQQQ | |
|---|---|---|
Market Cap | $23.11B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $118.52 | $97.60 |
52-Week Low | $67.38 | $36.31 |
Enterprise Value | $19.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
SQQQ trades at $42.68, down 0.26% with a bullish technical signal from moving averages but neutral oscillators. The ETF faces fundamental challenges as a leveraged short product with no traditional valuation metrics. Recent news highlights SQQQ's role as a tactical hedging tool against QQQ, though articles warn of significant long-term value erosion due to daily resets.
Outlook remains high-risk with SQQQ suitable only for sophisticated investors seeking short-term Nasdaq 100 downside protection. The primary risk is structural decay from daily rebalancing, making long-term holding detrimental. Analyst sentiment is cautious, emphasizing timing-dependent utility rather than investment merit.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
